Prophase Labs Inc Financials
This page shows Prophase Labs Inc (PRPH) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 17 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
A shrinking revenue base left fixed operating costs exposed, pushing the balance sheet to carry the business.
By FY2024, external financing stopped solving the cash problem: the company took in$14.2M from financing but finished with only$678K of cash. After two straight years of negative operating cash flow, working capital tightened enough that current liabilities now exceed current assets, so new capital appears to be covering near-term operating needs rather than rebuilding liquidity.
The business has moved from a cash-generating phase to a self-funding gap: free cash flow shifted from
This is more than a demand slowdown; it looks like a cost structure mismatch. SG&A reached
Financial Health Signals
Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →
Health score ≠ stock price. This rates the quality of Prophase Labs Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Prophase Labs Inc has an operating margin of -415.4%, meaning the company retains $-415 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is up from -570.6% the prior year.
Prophase Labs Inc's revenue declined 35.8% year-over-year, from $6.8M to $4.3M. This contraction results in a growth score of 0/100.
Prophase Labs Inc has elevated debt relative to equity (D/E of 16.07), meaning the company relies heavily on borrowed funds. This high leverage results in a low score of 0/100, reflecting increased financial risk.
Prophase Labs Inc's current ratio of 0.06 is below the typical benchmark, resulting in a score of 0/100. This tight liquidity could limit financial flexibility if cash inflows slow.
While Prophase Labs Inc generated -$8.3M in operating cash flow, capex of $0 consumed most of it, leaving -$8.3M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.
Prophase Labs Inc generates a -420.3% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is up from -725.7% the prior year.
Prophase Labs Inc passes 3 of 9 financial strength tests. 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), 1 of 2 efficiency signals pass.
For every $1 of reported earnings, Prophase Labs Inc generates $0.57 in operating cash flow (-$8.3M OCF vs -$14.7M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Prophase Labs Inc earns $-2.6 in operating income for every $1 of interest expense (-$18.0M vs $6.9M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
Earnings & Revenue
Prophase Labs Inc generated $4.3M in revenue in fiscal year 2025. This represents a decrease of 35.8% from the prior year.
Prophase Labs Inc's EBITDA was -$13.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 59.3% from the prior year.
Prophase Labs Inc reported -$14.7M in net income in fiscal year 2025. This represents an increase of 72.4% from the prior year.
Prophase Labs Inc earned $-1.74 per diluted share (EPS) in fiscal year 2025. This represents an increase of 93.5% from the prior year.
Cash & Balance Sheet
Prophase Labs Inc generated -$8.3M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 54.8% from the prior year.
Prophase Labs Inc held $90K in cash against $500K in long-term debt as of fiscal year 2025.
Prophase Labs Inc had 46M shares outstanding in fiscal year 2025. This represents an increase of 1445.8% from the prior year.
Margins & Returns
Prophase Labs Inc's gross margin was 31.9% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 34.1 percentage points from the prior year.
Prophase Labs Inc's operating margin was -415.4% in fiscal year 2025, reflecting core business profitability. This is up 155.2 percentage points from the prior year.
Prophase Labs Inc's net profit margin was -339.3% in fiscal year 2025, showing the share of revenue converted to profit. This is up 448.9 percentage points from the prior year.
Prophase Labs Inc's ROE was -420.3% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 305.5 percentage points from the prior year.
Capital Allocation
Prophase Labs Inc invested $107K in research and development in fiscal year 2025. This represents a decrease of 82.0% from the prior year.
Prophase Labs Inc invested $0 in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 100.0% from the prior year.
PRPH Income Statement
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $784K-11.2% | $883K-29.2% | $1.2M-12.9% | $1.4M-4.2% | $1.5M+5.5% | $1.4M-5.9% | $1.5M-36.2% | $2.4M |
| Cost of Revenue | $537K-46.6% | $1.0M+96.1% | $513K-43.3% | $905K-45.0% | $1.6M+36.9% | $1.2M-27.6% | $1.7M-31.3% | $2.4M |
| Gross Profit | $247K+300.8% | -$123K-116.8% | $734K+39.5% | $526K+450.7% | -$150K-169.8% | $215K+238.7% | -$155K-158.3% | -$60K |
| R&D Expenses | $0-100.0% | $6K+50.0% | $4K-95.9% | $97K+61.7% | $60K-50.8% | $122K-12.9% | $140K-48.5% | $272K |
| SG&A Expenses | $6.0M+28.9% | $4.6M+0.2% | $4.6M+13.0% | $4.1M-76.0% | $17.1M+159.9% | $6.6M-5.2% | $6.9M-5.0% | $7.3M |
| Operating Income | -$5.7M-20.2% | -$4.8M-22.3% | -$3.9M-6.3% | -$3.7M+78.8% | -$17.3M-166.8% | -$6.5M+10.3% | -$7.2M+5.3% | -$7.6M |
| Interest Expense | $4.3M+174.9% | $1.5M+163.9% | $587K+8.9% | $539K-59.2% | $1.3M+32.9% | $993K+90.2% | $522K+1.4% | $515K |
| Income Tax | -$622K-296.2% | -$157K-120.2% | $779K | $0-100.0% | $14.6M+680.4% | -$2.5M-9.7% | -$2.3M+10.9% | -$2.6M |
| Net Income | -$7.4M-8.2% | -$6.8M-52.9% | -$4.5M-212.8% | $4.0M+111.5% | -$34.4M-421.6% | -$6.6M-7.1% | -$6.2M+1.8% | -$6.3M |
| EPS (Diluted) | N/A | $-0.16-45.5% | $-0.11-200.0% | $0.11 | N/A | $-0.35-6.1% | $-0.33+8.3% | $-0.36 |
PRPH Balance Sheet
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $59.9M-8.9% | $65.7M+56.3% | $42.0M-16.1% | $50.1M-20.7% | $63.2M-31.2% | $91.8M-2.0% | $93.7M+4.0% | $90.0M |
| Current Assets | $3.1M-59.5% | $7.8M-68.4% | $24.6M-0.8% | $24.8M-19.2% | $30.6M-27.5% | $42.2M-4.3% | $44.1M-2.0% | $45.0M |
| Cash & Equivalents | $90K-77.8% | $405K+139.6% | $169K+92.0% | $88K-87.0% | $678K+35.3% | $501K-71.9% | $1.8M+51.5% | $1.2M |
| Inventory | $70K-73.7% | $266K-68.0% | $830K-27.5% | $1.1M+0.2% | $1.1M-71.2% | $4.0M+2.6% | $3.9M+2.9% | $3.8M |
| Accounts Receivable | $1.5M-53.2% | $3.3M-83.7% | $20.1M-0.6% | $20.2M+0.7% | $20.1M-36.6% | $31.6M-3.9% | $32.9M-6.2% | $35.1M |
| Goodwill | $4.0M0.0% | $4.0M-24.1% | $5.2M0.0% | $5.2M0.0% | $5.2M0.0% | $5.2M0.0% | $5.2M0.0% | $5.2M |
| Total Liabilities | $56.4M-4.2% | $58.8M+92.3% | $30.6M-12.5% | $35.0M-37.3% | $55.8M+4.0% | $53.7M+8.2% | $49.6M+9.8% | $45.2M |
| Current Liabilities | $53.1M-4.0% | $55.3M+115.7% | $25.6M+6.5% | $24.1M-25.2% | $32.1M+12.0% | $28.7M+2.4% | $28.0M+17.2% | $23.9M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $3.5M-48.9% | $6.9M-40.0% | $11.4M-24.4% | $15.1M+105.6% | $7.4M-80.7% | $38.1M-13.5% | $44.1M-1.8% | $44.9M |
| Retained Earnings | -$73.1M-11.3% | -$65.7M-11.6% | -$58.9M-8.2% | -$54.4M+6.8% | -$58.4M-143.0% | -$24.0M-37.8% | -$17.4M-54.5% | -$11.3M |
PRPH Cash Flow Statement
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$1.2M+64.7% | -$3.5M-1311.3% | -$247K+92.7% | -$3.4M+3.9% | -$3.5M+12.9% | -$4.0M+16.6% | -$4.8M+5.8% | -$5.1M |
| Capital Expenditures | $0 | $0 | $0 | $0-100.0% | $40K+4100.0% | -$1K | $0-100.0% | $867K |
| Free Cash Flow | -$1.2M+64.7% | -$3.5M-1311.3% | -$247K+92.7% | -$3.4M+5.0% | -$3.6M+11.9% | -$4.0M+16.6% | -$4.8M+19.4% | -$6.0M |
| Investing Cash Flow | $0 | $0-100.0% | $67K-92.1% | $853K+2232.5% | -$40K+58.8% | -$97K-178.2% | $124K-94.9% | $2.4M |
| Financing Cash Flow | $915K-75.4% | $3.7M+1326.1% | $261K-86.5% | $1.9M-48.1% | $3.7M+30.8% | $2.9M-46.3% | $5.3M+134.4% | $2.3M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | $0 | $0 | $0 | $0 |
PRPH Financial Ratios
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 31.5%+45.4pp | -13.9%-72.8pp | 58.9%+22.1pp | 36.8%+46.8pp | -10.0%-25.2pp | 15.2%+25.5pp | -10.3%-7.8pp | -2.5% |
| Operating Margin | -730.4%-190.8pp | -539.5%-227.3pp | -312.3%-56.3pp | -256.0%+901.3pp | -1157.3%-699.7pp | -457.6%+23.0pp | -480.6%-156.7pp | -323.9% |
| Net Margin | -943.6%-169.1pp | -774.5%-415.9pp | -358.6%-635.8pp | 277.2%+2577.0pp | -2299.8%-1834.6pp | -465.2%-56.1pp | -409.1%-143.2pp | -265.9% |
| Return on Equity | -210.9%-111.2pp | -99.7%-60.6pp | -39.1%-65.3pp | 26.2%+493.5pp | -467.3%-450.0pp | -17.3%-3.3pp | -14.0%0.0pp | -14.0% |
| Return on Assets | -12.4%-2.0pp | -10.4%+0.2pp | -10.6%-18.6pp | 7.9%+62.3pp | -54.4%-47.2pp | -7.2%-0.6pp | -6.6%+0.4pp | -7.0% |
| Current Ratio | 0.06-0.1 | 0.14-0.8 | 0.96-0.1 | 1.03+0.1 | 0.95-0.5 | 1.47-0.1 | 1.58-0.3 | 1.88 |
| Debt-to-Equity | 16.07+7.5 | 8.58+5.9 | 2.68+0.4 | 2.31-5.3 | 7.60+6.2 | 1.41+0.3 | 1.13+0.1 | 1.01 |
| FCF Margin | -156.9%+237.9pp | -394.8%-375.0pp | -19.8%+216.5pp | -236.3%+1.9pp | -238.2%+47.1pp | -285.2%+36.7pp | -321.9%-67.0pp | -255.0% |
Note: The current ratio is below 1.0 (0.06), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Frequently Asked Questions
What is Prophase Labs Inc's annual revenue?
Prophase Labs Inc (PRPH) reported $4.3M in total revenue for fiscal year 2025. This represents a -35.8% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Prophase Labs Inc's revenue growing?
Prophase Labs Inc (PRPH) revenue declined by 35.8% year-over-year, from $6.8M to $4.3M in fiscal year 2025.
Is Prophase Labs Inc profitable?
No, Prophase Labs Inc (PRPH) reported a net income of -$14.7M in fiscal year 2025, with a net profit margin of -339.3%.
What is Prophase Labs Inc's EBITDA?
Prophase Labs Inc (PRPH) had EBITDA of -$13.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Prophase Labs Inc have?
As of fiscal year 2025, Prophase Labs Inc (PRPH) had $90K in cash and equivalents against $500K in long-term debt.
What is Prophase Labs Inc's gross margin?
Prophase Labs Inc (PRPH) had a gross margin of 31.9% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Prophase Labs Inc's operating margin?
Prophase Labs Inc (PRPH) had an operating margin of -415.4% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Prophase Labs Inc's net profit margin?
Prophase Labs Inc (PRPH) had a net profit margin of -339.3% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Prophase Labs Inc's return on equity (ROE)?
Prophase Labs Inc (PRPH) has a return on equity of -420.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Prophase Labs Inc's free cash flow?
Prophase Labs Inc (PRPH) generated -$8.3M in free cash flow during fiscal year 2025. This represents a 54.8% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Prophase Labs Inc's operating cash flow?
Prophase Labs Inc (PRPH) generated -$8.3M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Prophase Labs Inc's total assets?
Prophase Labs Inc (PRPH) had $59.9M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Prophase Labs Inc's capital expenditures?
Prophase Labs Inc (PRPH) invested $0 in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Prophase Labs Inc spend on research and development?
Prophase Labs Inc (PRPH) invested $107K in research and development during fiscal year 2025.
What is Prophase Labs Inc's current ratio?
Prophase Labs Inc (PRPH) had a current ratio of 0.06 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is Prophase Labs Inc's debt-to-equity ratio?
Prophase Labs Inc (PRPH) had a debt-to-equity ratio of 16.07 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Prophase Labs Inc's return on assets (ROA)?
Prophase Labs Inc (PRPH) had a return on assets of -24.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Prophase Labs Inc's cash runway?
Based on fiscal year 2025 data, Prophase Labs Inc (PRPH) had $90K in cash against an annual operating cash burn of $8.3M. This gives an estimated cash runway of approximately 0 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Prophase Labs Inc's Piotroski F-Score?
Prophase Labs Inc (PRPH) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Prophase Labs Inc's earnings high quality?
Prophase Labs Inc (PRPH) has an earnings quality ratio of 0.57x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Prophase Labs Inc cover its interest payments?
Prophase Labs Inc (PRPH) has an interest coverage ratio of -2.6x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Prophase Labs Inc?
Prophase Labs Inc (PRPH) scores 0 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.